CV Lattes
ORCID
Google Scholar Citations
Secretaria da Saúde (São Paulo - Estado). Coordenadoria de Controle de Doenças (CCD). Instituto Adolfo Lutz (IAL) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Holds a degree in Biotechnology from the Federal University of Pará (2019). During his undergraduate studies, he was a Scientific Initiation fellow at the Evandro Chagas Institute (2017-2019), focusing on arbovirology. He is currently a master's graduate (2022) and a PhD student (2022 - present) in the Interunit Graduate Program in Biotechnology at the University of São Paulo (USP), working in collaboration with the Butantan Institute, the Institute for Technological Research (IPT), and the Adolfo Lutz Institute. As part of his PhD, he is conducting a research exchange at the Icahn School of Medicine, Mount Sinai Hospital, in New York (2025). He has consolidated experience in the field of Immunobiotechnology, with an emphasis on arboviruses, cell culture, Phage Display, molecular biology, recombinant protein expression and purification, as well as serological techniques. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Antibodies against SAR-CoV-2 are essential for understanding and fighting the COVID-19 pandemic. They perform some functions, such as elimination of the virus from infected patients, reagents for rapid diagnoses, constitute the first line of treatment for hospitalized patients and are the main objective of vaccine development. The vaccines and therapeutic antibodies currently available we…
Most current therapeutic antibodies for COVID-19 were developed to the Spike protein of SARS-CoV-2. However, their effectiveness has been diminished due to antigenic variation, driven mainly by mutations in the receptor-binding domain (RBD) of the Spike protein, highlighting the need of searching for broadly neutralizing antibodies that can target both existing and future variants. In thi…
| 1 / 1 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 2 / 2 | All Scholarships |
| Associated processes | |